As I write this, it’s the evening before I start receiving Uplizna (inebilizumab-cdon) infusions, a preventive treatment for my neuromyelitis optica spectrum disorder (NMOSD). I’ll admit, I’m feeling anxious. Here’s how Uplizna works: Astrocytes are a type of cell that helps nerves work properly. On the surface of…
Uplizna (inebilizumab-cdon)
Uplizna (inebilizumab) reduces the number and size of subclinical lesions — those that cause no apparent symptoms — in the spinal cord of people with neuromyelitis optica spectrum disorder (NMOSD) about six months after the start of treatment. That’s according to a new analysis from the Phase…
Uplizna (inebilizumab) reduces the formation of asymptomatic lesions in the nerves that connect the eyes to the brain in people with neuromyelitis optica spectrum disorder (NMOSD), according to a new data analysis from the Phase 2/3 N-MOmentum trial. Asymptomatic, or subclinical, lesions are those that don’t lead to…
When I was diagnosed with neuromyelitis optica (NMO) in 2012, the U.S. Food and Drug Administration (FDA) hadn’t yet approved any medications specifically to treat this disease. However, doctors could select various therapies to help patients prevent or deal with attacks. When NMO patients had an attack, doctors treated…
Recent Posts
- Pure oxygen therapy may reduce inflammation in NMOSD: Study
- How NMOSD has quietly shaped my experience of pain
- Global study finds genetic signature in blood that identifies NMOSD
- Suddenly, seemingly out of nowhere, I found a sense of empowerment
- Soliris reduces relapse rates in AQP4-positive NMOSD patients: Study